Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

647

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

November 30, 2028

Conditions
Tuberculosis InfectionHousehold ContactsChildrenAdolescentTuberculosis Infection, LatentTuberculosis
Interventions
DRUG

Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks

Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided to all participants.

DRUG

Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks

Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided only to participants with a positive IGRA result at baseline.

Trial Locations (13)

Unknown

Hospital Dr. Carlos Cisterna, Calama

Hospital de Coquimbo, Coquimbo

Hospital San Juan de Dios de La Serena, La Serena

Hospital Claudio Vicuña, San Antonio

Hospital Dr. Gustavo Fricke, Viña del Mar

Hospital de Niños Roberto del Río, Independencia

Hospital Luis Calvo Mackenna, Providencia

Complejo Asistencial Dr. Sótero Del Río, Puente Alto

Hospital El Pino, San Bernardo

Hospital Clínico Félix Bulnes, Santiago

Hospital Clínico San Borja Arriarán, Santiago

Hospital San Juan de Dios de Santiago, Santiago

Hospital Alto Hospicio, Alto Hospicio

All Listed Sponsors
lead

Pontificia Universidad Catolica de Chile

OTHER

NCT07086820 - Window Prophylaxis for Pediatric Tuberculosis Prevention Trial | Biotech Hunter | Biotech Hunter